@article{767f18866d7348f9aa77d9884828985c,
title = "American Heart Association Precision Medicine Platform Addresses Challenges in Data Sharing",
abstract = "AHA{\textquoteright}s PMP has enabled secure delivery of data through agile workspaces that scale with the high-performance compute needs of researchers and allow flexibility in the ready-to-run analysis tools. By listening and partnering with end users, we have overcome many of the hurdles facing researchers today including outdated data governance policies, insufficient data documentation, and inability of cloud-based environments to scale up resources for performance and allow researchers to personalize their workspaces with their own tools and pipelines.",
keywords = "clinical study, computational biology, database, machine learning, registries",
author = "Stevens, {Laura M.} and {De Lemos}, {James A.} and Das, {Sandeep R.} and Christine Rutan and Alger, {Heather M.} and Elkind, {Mitchell S.V.} and Juan Zhao and Kritika Iyer and Figueroa, {C. Alberto} and Hall, {Jennifer L.}",
note = "Funding Information: This project was supported by the American Heart Association (AHA). AHA{\textquoteright}s COVID-19 CVD Registry is partially supported by generous funds from the Gordon and Betty Moore Foundation. Funding Information: We would like to thank all of the members of the American Heart Association (AHA) COVID-19 Steering Committee for volunteering their time and expertise to this initiative. The Get With The Guidelines programs are provided by the AHA. The Precision Medicine Platform was established by the AHA, is powered by Amazon Web Services, and is supported by Hitachi Vantara. Funding Information: L.M. Stevens, Dr Alger, Dr Hall, and C. Rutan are employees of the American Heart Association. Dr Hall is an adjunct professor at the University of Minnesota. Drs de Lemos and Elkind are unpaid officers of the American Heart Association. Dr de Lemos discloses receiving grant support from Abbott Diagnostics and Roche Diagnostics and consulting income from Abbott Diagnostics, Ortho Clinical Diagnostics, Quidel Cardiovascular, Amgen, Regeneron, Eli Lilly and Novo Nordisk, and Janssen. Dr Elkind discloses receiving study drug in-kind from the BMS-Pfizer Alliance for Eliquis and ancillary research funding from Roche for an NIH-funded trial of stroke prevention; receiving royalties from UpToDate for chapters related to stroke; and receiving funding from NINDS, NHLBI, and the Leducq Foundation. Dr Figueroa discloses he is a cofounder of AngioInsight, Inc. The other authors report no conflicts. Publisher Copyright: {\textcopyright} 2021 Lippincott Williams and Wilkins. All rights reserved.",
year = "2021",
month = sep,
day = "1",
doi = "10.1161/CIRCOUTCOMES.121.007949",
language = "English (US)",
volume = "14",
pages = "E007949",
journal = "Circulation: Cardiovascular Quality and Outcomes",
issn = "1941-7713",
publisher = "Lippincott Williams and Wilkins",
number = "9",
}